Because the targeting of CSCs has been viewed as an important strategy for long-lasting treatment, a number of studies have focused on the identification of CSC markers such as CD44, CD24, epithelial cell surface antigen (ESA), and aldehyde dehydrogenase 1 (ALDH1) in breast cancer. This evidence concerns the gene CD44 and breast cancer.